Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock.

SGMO has been the topic of several other research reports. Wall Street Zen downgraded Sangamo Therapeutics to a “strong sell” rating in a research note on Saturday, January 31st. Barclays reiterated an “equal weight” rating and issued a $1.00 price target (down from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.33.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.40 on Tuesday. Sangamo Therapeutics has a 12 month low of $0.35 and a 12 month high of $1.24. The stock has a market cap of $134.60 million, a P/E ratio of -0.91 and a beta of 1.28. The company has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $0.51.

Institutional Trading of Sangamo Therapeutics

Institutional investors have recently bought and sold shares of the stock. Meritage Portfolio Management boosted its stake in shares of Sangamo Therapeutics by 37.3% during the 2nd quarter. Meritage Portfolio Management now owns 127,000 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 34,500 shares during the period. Wealth Management Associates Inc. boosted its holdings in Sangamo Therapeutics by 34.8% during the 2nd quarter. Wealth Management Associates Inc. now owns 307,800 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 79,400 shares during the period. R Squared Ltd bought a new position in Sangamo Therapeutics in the 2nd quarter valued at $28,000. Sanders Morris Harris LLC bought a new stake in shares of Sangamo Therapeutics during the second quarter worth $102,000. Finally, Oracle Investment Management Inc. purchased a new stake in shares of Sangamo Therapeutics during the third quarter valued at $677,000. 56.92% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.